PD Dr. med. Roman Iakoubov

Beruflicher Werdegang | Ausbildung

Klinik und Poliklinik für Innere Medizin II, TUM Klinikum, München

• seit 04/2025
  Zertifizierung der Ambulanz als „Diabeteszentrum DDG“
• seit 12/2020
  Oberarzt und Leitung Diabetes-Ambulanz
• 04/2019 – 11/2020 
  Funktionsoberarzt und Leitung Diabetes-Ambulanz
• seit 04/2019
  Funktionsoberarzt und Leitung Diabetes-Ambulanz
• 09/2009 – 03/2019
  Assistenzarzt Innere Medizin

10/2006 – 08/2009
Postdoctoral Fellow bei Professor Dr. Patricia L. Brubaker, Department of Physiology, University of Toronto, Kanada

07/2005 – 10/2006
Assistenzarzt Innere Medizin, Medizinische Klinik I (Gastroenterologie, Nephrologie und Transplantationsmedizin), Klinikum Merheim, Köln

1998 – 2005
Studium der Humanmedizin an der Medizinischen Hochschule Hannover
 

Qualifikationen

• 11/2025: Lehrbefugnis für das Fachgebiet „Innere Medizin mit Schwerpunkt Endokrinologie und Diabetologie"
• 01/2020: Zulassung als Diabetologe DDG
• 03/2017: Zulassung als Facharzt für Innere Medizin und Endokrinologie und Diabetologie
• 03/2007: Abschluss Promotion zum Thema „Die Bedeutung der Protein Kinase C Isoformen PKCα und PKCβ für das Acetylcholin-induzierte Calcium-Signal in den pankreatischen β-Zellen der Maus"
• 06/2005: Staatsexamen Medizin und Approbation als Arzt
   

Sprachen

Englisch, Deutsch und Russisch fließend
 

Publikationen

• Koehler F, Koehler J, Bramlage P, Vettorazzi E, Wegscheider K, Lezius S, Spethmann S, Iakoubov R, Vijayan A, Winkler S, Melzer C, Schütt K, Dessapt-Baradez C, Paar WD, Koehler K, Müller-Wieland D. Impact of telemedical management on hospitalization and mortality in heart failure patients with diabetes: a post-hoc subgroup analysis of the TIM-HF2 trial. Cardiovasc Diabetol. 2024 Jun 12;23(1):198.
• Triebelhorn J, Schneider J, Spinner CD, Iakoubov R, Voit F, Wagner L, Erber J, Rothe K, Berthele A, Pernpeintner V, Strauß EM, Renders L, Willmann A, Minic M, Vogel E, Christa C, Hoffmann D, Protzer U, Jeske SD. Clinical and immunological outcomes of SARS-CoV-2-infected vaccine responders, vaccine non-responders, and unvaccinated patients evaluated for neutralizing monoclonal antibody treatment at a single German tertiary care center: a retrospective cohort study with prospective follow-up. Infection. 2024 Jun;52(3):1143-1151.
• Heissig B, Salama Y, Iakoubov R, Vehreschild JJ, Rios R, Nogueira T, Vehreschild MJGT, Stecher M, Mori H, Lanznaster J, Adachi E, Jakob C, Tabe Y, Ruethrich M, Borgmann S, Naito T, Wille K, Valenti S, Hower M, Hattori N, Rieg S, Nagaoka T, Jensen BE, Yotsuyanagi H, Hertenstein B, Ogawa H, Wyen C, Kominami E, Roemmele C, Takahashi S, Rupp J, Takahashi K, Hanses F, Hattori K, On Behalf Of The Leoss Study Group. COVID-19 Severity and Thrombo-Inflammatory Response Linked to Ethnicity.  Biomedicines. 2022 Oct 12;10(10):2549.
• Koehler J, Ritzer B, Weidlich S, Gebhardt F, Kirchhoff C, Gempt J, Querbach C, Hoffmann D, Haller B, Schmid RM, Schneider J, Spinner CD, Iakoubov R. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.  Infection. 2021 Dec;49(6):1313-1318.
• Gaitzsch E, Passerini V, Khatamzas E, Strobl CD, Muenchhoff M, Scherer C, Osterman A, Heide M, Reischer A, Subklewe M, Leutbecher A, Tast B, Ruhle A, Weiglein T, Stecher SS, Stemmler HJ, Dreyling M, Girl P, Georgi E, Wölfel R, Mateyka L, D'Ippolito E, Schober K, Busch DH, Kager J, Spinner CD, Treiber M, Rasch S, Lahmer T, Iakoubov R, Schneider J, Protzer U, Winter C, Ruland J, Quante M, Keppler OT, von Bergwelt-Baildon M, Hellmuth J, Weigert O. COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma.  Hemasphere. 2021 Jun 28;5(7):e603.
• Würstle S, Spinner CD, Voit F, Hoffmann D, Hering S, Weidlich S, Schneider J, Zink A, Treiber M, Iakoubov R, Schmid RM, Protzer U, Erber J. Self-sampling versus health care professional-guided swab collection for SARS-CoV-2 testing.  Infection. 2021 Oct;49(5):927-934.
• Schneider J, Mijočević H, Ulm K, Ulm B, Weidlich S, Würstle S, Rothe K, Treiber M, Iakoubov R, Mayr U, Lahmer T, Rasch S, Herner A, Burian E, Lohöfer F, Braren R, Makowski MR, Schmid RM, Protzer U, Spinner C, Geisler F. SARS-CoV-2 serology increases diagnostic accuracy in CT-suspected, PCR-negative COVID-19 patients during pandemic.  Respir Res. 2021 Apr 23;22(1):119.
• Deschler S, Kager J, Erber J, Fricke L, Koyumdzhieva P, Georgieva A, Lahmer T, Wiessner JR, Voit F, Schneider J, Horstmann J, Iakoubov R, Treiber M, Winter C, Ruland J, Busch DH, Knolle PA, Protzer U, Spinner CD, Schmid RM, Quante M, Böttcher K. Mucosal-Associated Invariant T (MAIT) Cells Are Highly Activated and Functionally Impaired in COVID-19 Patients.  Viruses. 2021 Feb 3;13(2):241.
• Spinner CD, Schulz S, Bauer U, Schneider J, Bobardt J, Von Werder A, Schmid RM, Zink A, Wolf E, Iakoubov R. Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: the TAF-IR Study. Antivir Ther. 2018;23(7):629-632.
• Noe S, von Werder A, Iakoubov R, Schneider H, Thaler M, Luppa P, Neu B. Dynamics of Adrenocorticotropin after Application of Metyrapone. Exp Clin Endocrinol Diabetes. 2017 Jan;125(1):53-56.
• Spinner CD, Kern KE, Zink A, Wolf E, Balogh A, Noe S, Von Werder A, Schwerdtfeger C, Schmid RM, Iakoubov R. Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study. Antivir Ther. 2016;21(7):627-631.
• Thaler MA, Iakoubov R, Bietenbeck A, Luppa PB. Clinically relevant lot-to-lot reagent difference in a commercial immunoturbidimetric assay for glycated hemoglobin A1c. Clin Biochem. 2015 Nov;48(16-17):1167-70.
• Kühnen P, Matthae R, Arya V, Hauptmann K, Rothe K, Wächter S, Singer M, Mohnike W, Eberhard T, Raile K, Lauffer LM, Iakoubov R, Hussain K, Blankenstein O. Occurrence of giant focal forms of congenital hyperinsulinism with incorrect visualization by (18) F DOPA-PET/CT scanning. Clin Endocrinol (Oxf). 2014 Dec;81(6):847-54.
• Iakoubov R, Lauffer LM. T1R3: how to indulge the gut's sweet tooth. Am J Physiol Endocrinol Metab. 2012 Oct 1;303(7):E813-4.
• Sangle GV, Lauffer LM, Grieco A, Trivedi S, Iakoubov R, Brubaker PL. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Endocrinology. 2012 Feb;153(2):564-73.
• Iakoubov R, Ahmed A, Lauffer LM, Bazinet RP, Brubaker PL. Essential role for protein kinase Cζ in oleic acid-induced glucagon-like peptide-1 secretion in vivo in the rat. Endocrinology. 2011 Apr;152(4):1244-52.
• Iakoubov R, Lauffer LM, Trivedi S, Kim YI, Brubaker PL. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology. 2009 Sep;150(9):4033-43.
• Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes. 2009 May;58(5):1058-66.
• Lauffer L, Iakoubov R, Brubaker PL. GPR119: "double-dipping" for better glycemic control. Endocrinology. 2008 May;149(5):2035-7
  Iakoubov R, Izzo A, Yeung A, Whiteside CI, Brubaker PL. Protein kinase Czeta is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells. Endocrinology. 2007 Mar;148(3):1089-98.
• Schaefer M, Mischak H, Schnell S, Griese A, Iakoubov R, Riepenhausen G, Schöfl C. Mechanisms of arginine-vasopressin-induced Ca2+ oscillations in beta-cells (HIT-T15): a role for oscillating protein kinase C. Endocrinology. 2004 Oct; 145 (10): 4635-44.
• Remizov O, Iakoubov R, Düfer M, Krippeit Drews P, Drews G, Waring M, Brabant G, Wienbergen A, Rustenbeck I, Schöfl C. Palmitate-induced Ca2+-signaling in pancreatic beta-cells. Mol Cell Endocrinol. 2003 Dec 30; 212(1-2): 1-9.